Jump Financial LLC Trims Stake in Moderna, Inc. (NASDAQ:MRNA)

by · The Cerbat Gem

Jump Financial LLC decreased its position in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) by 78.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,860 shares of the company’s stock after selling 57,886 shares during the quarter. Jump Financial LLC’s holdings in Moderna were worth $659,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in MRNA. Wilmington Savings Fund Society FSB grew its position in Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after buying an additional 587 shares during the period. Venturi Wealth Management LLC grew its position in shares of Moderna by 286.2% during the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after acquiring an additional 664 shares during the period. Compass Planning Associates Inc purchased a new position in shares of Moderna in the 4th quarter valued at about $37,000. Crowley Wealth Management Inc. acquired a new position in Moderna in the 4th quarter worth about $41,000. Finally, MassMutual Private Wealth & Trust FSB boosted its position in Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after purchasing an additional 389 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Trading Up 2.4 %

Shares of MRNA stock opened at $25.74 on Wednesday. Moderna, Inc. has a twelve month low of $23.15 and a twelve month high of $170.47. The company’s 50-day moving average price is $30.61 and its 200-day moving average price is $39.16. The stock has a market cap of $9.95 billion, a price-to-earnings ratio of -2.77 and a beta of 2.23.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on MRNA. Leerink Partners reduced their target price on Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a research note on Thursday, January 16th. Barclays cut shares of Moderna from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $111.00 to $45.00 in a research report on Tuesday, February 18th. Morgan Stanley dropped their target price on shares of Moderna from $39.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 9th. JPMorgan Chase & Co. reduced their price target on shares of Moderna from $40.00 to $33.00 and set an “underweight” rating for the company in a research report on Friday, March 21st. Finally, Citigroup began coverage on Moderna in a report on Thursday, March 13th. They issued a “neutral” rating and a $40.00 price objective on the stock. Four equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Moderna presently has a consensus rating of “Hold” and a consensus target price of $58.70.

Get Our Latest Report on MRNA

Moderna Profile

(Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Further Reading